Pomegranates, berries and walnuts contain only its precursors (ellagitannins), which gut bacteria convert to urolithin A in a two-step metabolism. That is why it has to be supplied as a high-purity ingredient.
Cohort studies show that the share of people who produce only urolithin A (the UM-A metabotype) falls from about 80% in childhood to about 55% after age 40, and around 10% of people produce none at all. The target population is precisely the group whose own production is declining.
Mechanistic studies have been published in Nature Medicine, Nature Metabolism and other journals; the scientific foundation of the category continues to be built by the global research community.
Disclaimer: this mechanism and its associated efficacy claims may not be used commercially without authorisation from the patent holder; Taiyi Health does not hold the corresponding patents.
Taiyi Health's Science Department has completed research on a new urolithin A pathway; patent filing in progress
Define the target consumer, use occasion and dosage form; oral and topical routes in parallel, with combination recommendations and claim language for the target market
Solve dispersion and stability of a poorly water-soluble active in aqueous and solid systems, and deliver samples ready for trial
Stability and stress testing, system compatibility, and formulation-level human efficacy evaluation
When finished products are required, Taiyi Health's ODM system takes over: formulation, sampling, validation and mass production
Every two weeks our patent analysis team reads the latest patent activity in the urolithin A field and writes a report that procurement and legal teams can both use, reviewed by our legal team before release. Subscription is free.
Taiyi Health's urolithin A branded-ingredient team
delivers science-backed ingredient and finished-product solutions with intellectual property risk under control